TABLE 4.

Summary of cefepime pharmacokinetic parameters for patients receiving CVVHDF

Patient	Dosing regimen	Cmax (μg/ml)	Cmin (μg/ml)	AUC0–24 (μg · h/ml)	t1/2 (h)	V (liter/kg)	CLS		UFRa (ml/min)	CRRT CLb			Sab
							ml/min	ml/min/kg		ml/min	ml/min/kg	%CLS
6	1 g every 24 h	44.8	5.8	600.7	8.0	0.30	38 ± 4	0.44 ± 0.04	18 ± 2	25 ± 6	0.28 ± 0.07	33 ± 10	0.73 ± 0.09
7	1 g every 24 h	25.7	3.5	344.9	8.2	0.58	67 ± 5	0.81 ± 0.06	20 ± 10	23 ± 8	0.27 ± 0.10	66 ± 18	0.65 ± 0.09
8	1 g every 12 h	36.2	13.6	581.8	8.3	0.35	58 ± 1	0.49 ± 0.01	14 ± 1	28 ± 1	0.24 ± 0.02	48 ± 1	0.92 ± 0.02
9	2 g every 24 h	72.9	10.4	979.2	8.4	0.32	26 ± 6	0.24 ± 0.06	20 ± 4	47 ± 5	0.44 ± 0.05	56 ± 14	0.73 ± 0.12
10	2 g every 24 h	79.1	6.9	1,009.9	6.7	0.21	36 ± 8	0.30 ± 0.07	23 ± 7	45 ± 2	0.37 ± 0.01	81 ± 19	0.93 ± 0.06
11	2 g every 24 h	63.6	12.2	890.9	9.9	0.26	23 ± 2	0.17 ± 0.01	13 ± 2	42 ± 1	0.31 ± 0.01	53 ± 4	0.78 ± 0.07
12	2 g every 24 h	90.8	20.4	1,306.8	10.9	0.34	22 ± 1	0.27 ± 0.02	14 ± 2	30 ± 1	0.36 ± 0.01	76 ± 4	0.75 ± 0.05
Mean ± SD					8.6 ± 1.4	0.34 ± 0.12	47 ± 0.12c	0.46 ± 0.17c	17 ± 4c	26 ± 5c	0.25 ± 0.04c	59 ± 16c	0.78 ± 0.10c

^aUFR, ultrafiltration rate. 

^bValues are means ± standard deviations calculated from parameter values determined during each of the four or five postdose sampling intervals for each patient: 1 to 2 h, 2 to 4 h, 4 to 8 h, 8 to 12 h, and 12 to 24 h (except with 12-h dosing interval regimens). 

^cMeans ± standard deviations calculated from means of the four or five parameter values determined for each individual patient.